Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series
by
Bouwer C, Claassen J, Dinan TG, Nemeroff CB
Department of Psychological Medicine,
University of Otago University,
Dunedin, New Zealand.
colin.bouwer@stonebow.otago.ac.nz
Depress Anxiety 2000; 12(1):44-50

ABSTRACT

Abnormalities of the hypothalamic-pituitary-adrenal (HPA) axis have long been implicated in major depression with hypercortisolaemia reported in typical depression and hypocortisolaemia in some studies of atypical depression. We report on the use of prednisone in treatment-resistant depressed patients with reduced plasma cortisol concentrations. Six patients with treatment-resistant major depression were found to complain of severe fatigue, consistent with major depression, atypical subtype, and to demonstrate low plasma cortisol levels. Prednisone 7.5 mg daily was added to the antidepressant regime. Five of six patients demonstrated significant improvement in depression on prednisone augmentation of antidepressant therapy. Although hypercortisolaemia has been implicated in some patients with depression, our findings suggest that hypocortisolaemia may also play a role in some subtypes of this disorder. In treatment-resistant depressed patients with fatigue and hypocortisolaemia, prednisone augmentation may be useful.

CRF
LHPA
Stress
Options
Pregnancy
21st century
Thymopoetin
Ketoconazole
Cushing's syndrome
Learned helpless rats
Glucocorticoids and mood
Neuroendocrinology of stress
Alcohol, suicide and serotonin
Suicide, serotonin and the HPA Axis

Refs
HOME
HedWeb
Cocaine.org
Future Opioids
BLTC Research
Superhappiness?
Paradise-Engineering
The Abolitionist Project
The Hedonistic Imperative
MDMA: Utopian Pharmacology

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family